[1] |
World Health Organization.World malaria report 2018[R]. Geneva: WHO, 2018.
|
[2] |
White NJ, Pukrittayakamee S, Hien TT, et al. Malaria[J]. Lancet, 2014, 383(9918): 723-735.
|
[3] |
Lacerda-Queiroz N, Brant F, Rodrigues DH, et al. Phosphatidylinositol 3-kinase γ is required for the development of experimental cerebral malaria[J]. PLoS One, 2015, 10(3): e0119633.
|
[4] |
Newton C.Severe falciparum malaria in children current understanding of pathophysiology and supportive treatment[J]. Pharmacol Ther, 1998, 79(1): 1-53.
|
[5] |
张逸龙, 潘卫庆. 恶性疟原虫对青蒿素产生抗性的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2015, 33(6): 418-424.
|
[6] |
Rousseau N, Picot S, Bienvenu AL.Erythropoietin combined with liposomal amphotericin B improves outcome during disseminated aspergillosis in mice[J]. Front Immunol, 2014, 5: 502.
|
[7] |
Hu RY, Cheng Y, Jing H, et al. Erythropoietin promotes the protective properties of transplanted endothelial progenitor cells against acute lung injury via PI3K/Akt pathway[J]. Shock, 2014, 42(4): 327-336.
|
[8] |
Belnoue E, Potter SM, Rosa DS, et al. Control of pathogenic CD8+ T cell migration to the brain by IFN-γ during experimental cerebral malaria[J]. Parasite Immunol, 2008, 30(10): 544-553.
|
[9] |
BRIAN de SOUZA J, Hafalla JCR, Riley EM, et al. Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease[J]. Parasitology, 2010, 137(5): 755-772.
|
[10] |
刘太平, 付雍, 徐文岳, 等. 脑型疟发生的免疫病理机制[J]. 中国寄生虫学与寄生虫病杂志, 2011, 29(1): 64-67.
|
[11] |
Wang J, Li Y, Shen Y, et al. PDL1 fusion protein protects against experimental cerebral malaria via repressing over-reactive CD8+ T cell responses[J]. Front Immunol, 2019, 9: 3157.
|
[12] |
Gogtay N, Kannan S, Thatte UM, ,et al. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria[J]. Cochrane Database Syst Rev, 2013(10): CD008492.
|
[13] |
Wei X, Li Y, Sun XD, et al. Erythropoietin protects against murine cerebral malaria through actions on host cellular immunity[J]. Infect Immun, 2014, 82(1): 165-173.
|
[14] |
杨志蕃, 庞维, 杜云婷, 等. L-精氨酸对实验性脑型疟疾的免疫调控机制研究[J]. 微生物学杂志, 2014, 34(6): 65-69.
|
[15] |
李培育, 高宏伟, 董天崴, 等. 不同来源的IL-10对脑疟小鼠免疫病理损伤的调控作用[J]. 哈尔滨医科大学学报, 2015, 49(4): 296-299, 304.
|
[16] |
Rénia L, Howland SW, Claser C, et al. Cerebral malaria[J]. Virulence, 2012, 3(2): 193-201.
|
[17] |
Poh CM, Howland SW, Grotenbreg GM, et al. Damage to the blood-brain barrier during experimental cerebral malaria results from synergistic effects of CD8+ T cells with different specificities[J]. Infect Immun, 2014, 82(11): 4854-4864.
|
[18] |
Conroy AL, Glover SJ, Hawkes M, et al. Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria[J]. Crit Care Med, 2012, 40(3): 952-959.
|
[19] |
Paré G, Ridker PM, Rose L, et al. Genome-wide association analysis of soluble ICAM-1 concentration reveals novel associations at the NFKBIK, PNPLA3, RELA, and SH2B3 loci[J]. PLoS Genet, 2011, 7(4): e1001374.
|
[20] |
Rousseau N, Picot S, Bienvenu AL.Erythropoietin combined with liposomal amphotericin B improves outcome during disseminated aspergillosis in mice[J]. Front Immunol, 2014, 5: 502.
|
[21] |
Aapro M, Osterwalder B, Scherhag A, et al. Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events[J]. Br J Cancer, 2009, 101(12): 1961-1971.
|
[22] |
Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial[J]. Lancet, 2003, 362(9392): 1255-1260.
|